T 1303/18 (UCB PHARMA / ROTIGOTINE POLYMORPH) of 21.11.2022
- European Case Law Identifier
- ECLI:EP:BA:2022:T130318.20221121
- Date of decision
- 21 November 2022
- Case number
- T 1303/18
- Petition for review of
- -
- Application number
- 08853236.1
- IPC class
- A61K 31/381C07D 333/20A61P 25/00
- Language of proceedings
- English
- Distribution
- Distributed to board chairmen (C)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- Abstract on EPC2000 Art 87(1)Abstract on Art 13(1) RPBA 2020
- Application title
- POLYMORPHIC FORM OF ROTIGOTINE
- Applicant name
- UCB Pharma GmbH
- Opponent name
- Interquim, S.A.
Hexal AG
Generics [UK] Limited
Luye Pharma AG
Wittkopp, Alexander
AMW GmbH
Alfred E. Tiefenbacher (GmbH & Co. KG) - Board
- 3.3.02
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 87(1)Rules of procedure of the Boards of Appeal 2020 Art 013(1)
- Keywords
- Earliest priority - identity of invention (no)
Amendment to appeal case (yes)
New allegation of fact - admitted (no)
Novelty - public prior use (yes)
Inventive step - auxiliary request 4 (no) - Catchword
- If the patent proprietor introduces various differences between the definition of a certain compound in a granted claim and that in the priority application and if despite these differences, the patent proprietor, in arguing that the effective date of the subject-matter of the granted claim is the claimed priority date, asserts that the compound of the granted claim is the same as that disclosed in the priority application, it is the patent proprietor who bears the burden of proving this assertion (point 2.13 of the reasons).
- Citing cases
- -
Order
For these reasons it is decided that:
The appeal is dismissed.